- All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
- Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
- Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.
- PMID: 36564566
- PubMed abstract
- Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
- Vertechy L, Boccia SM, Tiberi G, Avesani G, Corrado G, Fagotti A, Scambia G, Marchetti C.
- Int J Gynecol Cancer. 2022 Dec 23:ijgc-2022-003764. doi: 10.1136/ijgc-2022-003764. Epub ahead of print.
- PMID: 36564097
- PubMed abstract
- Source abstract
- Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
- Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
- Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.
- PMID: 36516847
- PubMed abstract
•• Commentary:
HRD-related morphology discovery in breast cancer by controlling for confounding factors.
- PMID: 36543118
- PubMed abstract
- Source abstract
- BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
- Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
- Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
- PMID: 36557020
- PubMed abstract
- Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
- Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL.
- Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.11.003. Epub ahead of print.
- PMID: 36564284
- PubMed abstract